Share-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2019

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Summary of Share-based Compensation Under Each Plan According to Change in Estimate

The table below shows the share-based compensation under each plan according to the change in estimate mentioned above .

	Year ended						Total expense		Total expense
Share-based compensation - Annual expense	2017/12/31		2018/12/31		2019/12/31		calculated		remaining
BSA 2014-A		—		—		—		945		—
Of which : expense related to non-executive officers		—		—		—		365		—
Of which : expense related to consultants		—		—		—		581		—
BSA 2014-B		—		—		—		1,045		—
Of which : expense related to non-executive officers		—		—		—		365		—
Of which : expense related to consultants		—		—		—		680		—
BSAAR 2014-A		—		—		—		43		—
Of which : expense related to non-executive officers		—		—		—		9		—
Of which : expense related to consultants		—		—		—		34		—
BSAAR 2014-B		—		—		—		191		0
Of which : expense related to non-executive officers		—		—		—		35		0
Of which : expense related to consultants		—		—		—		156		—
BSAAR 2014-C		—		—		—		189		0
Of which : expense related to non-executive officers		—		—		—		35		—
Of which : expense related to consultants		—		—		—		154		0

	Year ended						Total expense		Total expense
Share-based compensation - Annual expense	2017/12/31		2018/12/31		2019/12/31		calculated		remaining
BSA 2015-A		—		—		—		335		—
Of which : expense related to non-executive officers		—		—		—		178		—
Of which : expense related to consultants		—		—		—		157		—
BSA 2015-B		—		—		—		315		—
Of which : expense related to non-executive officers		—		—		—		178		—
Of which : expense related to consultants		—		—		—		138		—

	Year ended							Total expense		Total expense
Share-based compensation - Annual expense	2017/12/31		2018/12/31		2019/12/31			calculated		remaining
BSAAR 2016-A		—		—		—			—		—
Of which : expense related to executive officers		—		—		—			—		—
Of which : expense related to employees		—		—		—			—		—
BSAAR 2016-B		—		—		—			—		—
Of which : expense related to executive officers		—		—		—			—		—
Of which : expense related to employees		—		—		—			—		—
AGA D 2016-1		38		127		—			166		0
Of which : expense related to executive officers		7		25		—			32		0
Of which : expense related to employees		31		101		—			133		0
AGA D 2016-2		17		17		39			74		—
Of which : expense related to executive officers		3		3		8			14		—
Of which : expense related to employees		14		14		31			59		—
AGA S 2016-1		44		151		—			197		—
Of which : expense related to executive officers		—		—		—			—		—
Of which : expense related to employees		44		151		—			197		—
AGA S 2016-2		22		22		44			88		—
Of which : expense related to executive officers		—		—		—			—		—
Of which : expense related to employees		22		22		44			88		—
SO 2016-1		83		83		213			383		—
Of which : expense related to executive officers		13		13		36			63		—
Of which : expense related to employees		70		70		176			319		—
SO 2016-2		38		38		93			170		—
Of which : expense related to executive officers		6		6		16			28		—
Of which : expense related to employees		32		32		77			142		—
SO US 2016-1		12		12		(24	)		—		—
Of which : expense related to executive officers		—		—		—			—		—
Of which : expense related to employees		12		12		(24	)		—		—
SO US 2016-2		5		5		(11	)		—		—
Of which : expense related to executive officers		—		—		—			—		—
Of which : expense related to employees		5		5		(11	)		—		—

	Year ended							Total expense		Total expense
Share-based compensation - Annual expense	2017/12/31		2018/12/31		2019/12/31			calculated		remaining
BSA 2017-A		6		63		—			69		—
Of which : expense related to non-executive officers		4		43		—			47		—
Of which : expense related to employees		2		20		—			22		—
BSA 2017-B		3		66		—			70		0
Of which : expense related to non-executive officers		2		46		—			48		0
Of which : expense related to employees		1		21		—			22		0
AGA D 2017-1		1		17		199			217		—
Of which : expense related to executive officers		0		2		28			30		—
Of which : expense related to employees		1		15		171			187		—
AGA D 2017-2		2		29		56			131		44
Of which : expense related to executive officers		0		3		8			18		6
Of which : expense related to employees		2		26		48			113		37
AGA S 2017-1		—		—		209			209		—
Of which : expense related to executive officers		—		—		—			—		—
Of which : expense related to employees		—		—		209			209		—
AGA S 2017-2		2		24		45			104		34
Of which : expense related to executive officers		—		—		—			—		—
Of which : expense related to employees		2		24		45			104		34
SO 2017-1		2		28		27			61		4
Of which : expense related to executive officers		0		5		5			11		1
Of which : expense related to employees		2		23		22			50		4
SO 2017-2		3		48		2			81		28
Of which : expense related to executive officers		1		8		0			15		5
Of which : expense related to employees		3		39		2			66		23
SO US 2017-1		0		3		(4	)		—		0
Of which : expense related to executive officers		—		—		—			—		—
Of which : expense related to employees		0		3		(4	)		—		0
SO US 2017-2		0		5		(6	)		—		0
Of which : expense related to executive officers		—		—		—			—		—
Of which : expense related to employees		0		5		(6	)		—		0

	Year ended						Total expense		Total expense
Share-based compensation - Annual expense	2017/12/31		2018/12/31		2019/12/31		calculated		remaining
AGA D 2018		—		10		135		277		132
Of which : expense related to executive officers		—		2		21		43		21
Of which : expense related to employees		—		9		114		234		111
AGA S 2018		—		12		148		305		145
Of which : expense related to executive officers		—		—		—		—		—
Of which : expense related to employees		—		12		148		305		145
SO 2018		—		24		285		849		539
Of which : expense related to executive officers		—		3		40		118		75
Of which : expense related to employees		—		21		245		730		464
SO US 2018		—		3		25		76		48
Of which : expense related to executive officers		—		—		—		—		—
Of which : expense related to employees		—		3		25		76		48

	Year ended						Total expense		Total expense
Share-based compensation - Annual expense	2017/12/31		2018/12/31		2019/12/31		calculated		remaining
BSA 2019		—		—		7		26		20
Of which : expense related to executive officers		—		—		—		—		—
Of which : expense related to employees		—		—		7		26		20
AGA D 2019		—		—		35		242		207
Of which : expense related to executive officers		—		—		5		38		33
Of which : expense related to employees		—		—		29		204		175
AGA S 2019		—		—		41		288		246
Of which : expense related to executive officers		—		—		—		—		—
Of which : expense related to employees		—		—		41		288		246
SO 2019		—		—		86		599		513
Of which : expense related to executive officers		—		—		10		68		58
Of which : expense related to employees		—		—		76		531		455
SO US 2019		—		—		1		43		42
Of which : expense related to executive officers		—		—		—		—		—
Of which : expense related to employees		—		—		1		43		42

	Year ended						Total expense		Total expense
Share-based compensation - Annual expense	2017/12/31		2018/12/31		2019/12/31		calculated		remaining
TOTAL		278		787		1,645		7,787		2,004

Share Warrants

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Summary of Key Terms and Conditions of Share-Based Compensation Based

The key terms and conditions related to each program are detailed in the following tables:

Share-base compensation	2019	2017		2015		2014
Share warrants ( BSA )
		BSA 2017-A	BSA 2017-B	BSA 2015-A	BSA 2015-B	BSA 2014-A	BSA 2014-B
Date of the Shareholders meeting	06/15/2018	06/16/2017		04/02/2014		04/02/2014
Date of the Management Board meeting				01/09/2015		07/24/2014
Date of the decision and delegation of the Board of Directors to the CEO	10/18/2019	11/21/2017
Date of the CEO decision	10/31/2019	12/06/2017
Beneficiaries	Consultants	Consultants and officers		Consultants and officers		Consultants and officers
Total number of BSAAR subscribed	35,070	18,345	18,345	12,860	12,860	46,765	46,765
Total number of BSAAR voided	0	0	0	12,860	12,860	46,765	46,765
Total number of BSAAR  remaining	35,070	18,345	18,345	0	0	0	0
Issue Price	€1.23	€2.00		€0.01		€0.01
Excercise price	€12.32	€19.97		€35.95		€23.50
Estimated fair value - according to IFRS 2	€0.75	€3.78	€3.81	€25.33 /€26.89	€25.33 /€26.31	€15.61 /€24.84	€15.61 /€24.85
End of exercise period	05/31/2024	06/30/2022	07/15/2022	05/31/2019	11/30/2019	09/30/2018	02/28/2019
Valuation method used	Black & Scholes
Expected dividends	0%	0%		0%		0%
Expected volatility	40.0%	36.4%	35.7%	74.9%		74.9%
Risk-free interest rate	0%	0.0%		0.4%		0.4%
Expected life	0.7 years	6 years		4 years		4 years

Redeemable Warrants

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Summary of Key Terms and Conditions of Share-Based Compensation Based

Share-Based compensation	2 016	2 014
Redeemable share subscription warrants ( BSAAR )	BSAAR 2016-A and B	BSAAR 2014-A - B  and C
	Employees	Employees and Officers
Date of the Shareholders'  meeting	02/24/2015	04/02/2014
Date  of the Management Board Meeting	07/22/2016	09/16/2014
Date of the decision and delegation of the Board of Directors to the CEO
Date of the CEO decision
Total number of BSAAR subscribed	10,800	62,717
Total number of BSAAR voided	0	61,484
Total number of BSAAR exercised	0	1,233
Total number of BSAAR  remaining	10,800	0
Issue Price	€23.5	€23.5
Exercise period	From 01/01/2018 to 27/07/2020	voided on  09.2018 - 05.2019 and 07.2019
Estimated fair value - valued by expert opinion	€4.60	from €8.44 to €11.29
Valuation method used	Black & Scholes	Black & Scholes
Expected dividends	0%	0%
Expected volatility	75.4%	75.4%
Risk-free interest rate	0.0%	0.4%
Expected life	4 years	4 years

Free Shares

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Summary of Key Terms and Conditions of Share-Based Compensation Based

The key terms and conditions related to each program are detailed in the following tables:

Share-based compensation	2 019				2 019					2 018		2 017		2 016
Free shares (AGA)	AGA D				AGA S
	Officers(1)		Employees		Officers(1)		Employees		AGA D and S		AGA D and S 2017-1 and 2017-2		AGA D and S 2016-1 and 2016-2
Date of the Shareholders meeting	06/15/2018								06/15/2018		06/16/2017		06/21/2016
Date of the Management Board meeting													12/15/2016
Date of the decision and delegation of the Board of Directors to the CEO	07/18/2019								11/07/2018		11/22/2017
Date of the Executive Board Meeting	07/18/2019								11/22/2018		12/06/2017
Total number of AGA subscribed		3,000		16,070		0		17,556		35,800		41,196		30,709
Total number of AGA voided		0		450		0		702		1,872		9,846		5,429
Total number of AGA definitively vested		0		0		0		0		0		19,403		25,280
Total number of AGA remaining		3,000		15,620		0		16,854		33,928		11,947		0
Acquisition period	From 07/18/2019 to 09/16/2022								From 11/22/2018 to 12/31/2020		From 12/06/2017 to 12/31/2020		From 12/15/2016 to 12/15/2019
Valuation method used	Monte Carlo
Price of the share at the time of allocation	€17.06								€	20.02	€	21.95	€	20.78
Expected dividends	0%								0%		0%		0%
Expected volatility	40.16%								38.0%		53.7%		63.0%
Risk-free interest rate	0.0%								0.0%		0.0%		0.0%
Turnover rate	0.00%								15.00%		15.00%		15.00%
(1) : Chairman and CEO
The terms and conditions of the 2016 to 2018 allocations to the Chairman and CEO are provided in the Universal Registration Document or the financial statements for the relevant periods.
(1) : Chief executive officer

Stock Options

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Summary of Key Terms and Conditions of Share-Based Compensation Based

The key terms and conditions related to each program are detailed in the following tables:

Share-based compensation	2 019				2 018		2 017		2 016
Stock-options  (SO)	SO		SO US 1	SO US 2	SO 2018	SO US 2018	SO 1 et 2   2017	SO US 2017	SO 1 et 2   2016	SO US 2016
	Officers(1)	Employees	Employees	Employees	Employees and Offices	Employees	Employees and Offices	Employees	Employees and Offices	Employees
Date of the Shareholders meeting	06/15/2018			11/27/2019	06/15/2018		06/16/2017		06/21/2016
Date of the Management Board meeting									12/15/2016
Date of the decision and delegation of the Board of Directors to the CEO	07/18/2019			11/27/2019	11/07/2018		11/21/2017
Date of the CEO decision	07/18/2019			11/27/2019	11/07/2018		12/06/2017
Total number of SO subscribed	15,130	92,750	30,620	13,350	122,000	17,500	96,250	13,000	62,875	10,500
Total number of SO voided	0	1,780	0	0	2,000	3,000	21,577	13,000	13,169	10,500
Total number of SO definitively vested	0	0	0	0	0	0	0	0	49,706	0
Total number of SO remaining	15,130	90,970	30,620	13,350	120,000	14,500	74,673	0	0	0
Excercise price	€13.99		€16.9	€14.31	€16.00	€21.65	€17.91	€22.54	€15.79	€21.12
Vesting period	From 07/18/2019 to 09/16/2022			From 11/27/2019 to 01/16/2023	From 11/07/2018 to 12/31/2021		From 12/06/2017 to 12/31/2020		From 12/15/2016 to 12/15/2019
Exercise period	From 09/17/2022 to 09/17/2029			From 01/17/2023 to 01/17/2030	From 01/01/2022 to 12/31/2028		From 01/01/2021to 12/31/2027		From 12/16/2019 to 12/16/2026
Fair value	€4.59		€3.67	€3.23	€9.32	€6.9	€9.32		€10.3	€8.52
Valuation method used	Monte Carlo
Price of the share at the time of allocation	€17.06			€14.5	€22.12		€21.95		€20.79
Expected dividends	0%			0%	0%		0%		0%
Expected volatility	40.16%			40.0%	44.07%		53.7%		63.0%
Risk-free interest rate	0.0%			0.0%	0.0%		0.0%		0.0%
Turnover rate	0.00%			0.00%	15.00%		15.00%		15.00%

Performance Conditions

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Summary of Key Terms and Conditions of Share-Based Compensation Based

The SO and SO US stock option plans as well as certain free share plans (AGA "D") implemented in 2016, 2017, 2018 and 2019 are subject to internal performance conditions related to the progress of the Group's research and development programs, and to external performance conditions related to the evolution of the Company's stock price.

The other free share plans (AGA "S") are subject only to internal performance conditions.

20.5.1. Performance conditions of the 2019 plans

Plans	Evaluation date for performance conditions	Nature of internal conditions
SO 2019 SO US 2019 AGA D 2019	07/31/2022	66 2/3% of the instruments will be exercisable or definitively vested, and 100% of the free shares for the AGA S 2019 will be vested, regardless of the variation of the stock market price of the Company’s shares, if at least one of the three following conditions is fulfilled: (i) if a marketing authorization is granted or an application for marketing authorization is examined: •     by the European Medicines Agency (EMA) or the U.S. Food and Drug Administration (FDA) for elafibranor for NASH; or: •     by the U.S. Food and Drug Administration (FDA)/the competent European authorities in the field of IVD for NIS4 for NASH; or: (ii) if at least two of the four clinical trial among the following trials have delivered their principal results or are ongoing: •     Phase III clinical trials for elafibranor for PBC; or •     clinical trial evaluating elafibranor’s efficacy in NASH pediatric patients; or •     Phase IIb clinical trial or clinical trial aimed at registration for NTZ in fibrosis; or •     Clinical trial evaluating elafibranor or NTZ in combination therapy for NASH or for hepatic fibrosis; or: (iii) if at least a new licensing agreement, on one or another of Genfit’s products in one or several territories, is entered into by the Company.
		Nature of external conditions
		33 1/3 % of the instruments will be exercisable or definitively vested, in proportion to the variation of the Company’s stock market price as per the following breakdown: (i) if the Final Price is strictly lower than the Initial Price, the number of the Stock Options exercisable is equal to 0; (ii) if the Final Price is between (i) a value equal to or higher than the Initial Price and (ii) a value lower than the Ceiling Price, the number of Stock Options exercisable is equal to: [(Final Price / Initial Price)-1]/2 x 1/3 of number of Stock Options; (iii) if the Final Price is equal to or higher than the Ceiling Price, the number of Stock Options exercisable is equal to the entire one-third of the Stock Options allocated
SO US 2019-2	01/09/2023	Nature of internal conditions
		66 2/3 % of the instruments will be exercisable if at least if at least one of the three following conditions is fulfilled: (i) if elafibranor has been granted  marketing authorization by the European Medicines Agency (EMA) or the U.S. Food and Drug Administration (FDA) in NASH or PBC or NIS4 has been authorized by FDA or received CE marking from the EMA; (ii) a licensing agreement pertaining to elafibranor or NTZ has been signed for the U.S. market and/or for at least two of the five major European markets (Germany, France, Italy, United Kingdom, Spain) and/or Japan; (iii) at least two clinical trials for drug registration are underway. Nature of external conditions
		33 1/3 % of the instruments will be exercisable, in proportion to the variation of the Company’s stock market price as per the following breakdown: (i) if the Final Price is strictly lower than the Initial Price, the number of the Stock Options exercisable is equal to 0; (ii) if the Final Price is between (i) a value equal to or higher than the Initial Price and (ii) a value lower than the Ceiling Price, the number of Stock Options exercisable is equal to:  [(Final Price / Initial Price)-1]/2 x 1/3 of number of Stock Options; (iii) if the Final Price is equal to or higher than the Ceiling Price, the number of Stock Options exercisable is equal to the entire one-third of the Stock Options allocated.
		Nature of internal conditions
AGA S 2019	07/31/2022	The free shares will definitively vest upon the same internal performance conditions as the  SO 2019, SO US 2019 and AGA D 2019 plans